Seer, Inc. (SEER)
| Market Cap | 2.06B |
| Revenue (ttm) | 1.80M |
| Net Income (ttm) | n/a |
| Shares Out | 60.84M |
| EPS (ttm) | -1.40 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 239,935 |
| Open | 34.37 |
| Previous Close | 34.49 |
| Day's Range | 32.95 - 34.37 |
| 52-Week Range | 26.48 - 86.55 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 55.00 (+64.3%) |
| Est. Earnings Date | Nov 9, 2021 |
About SEER
Seer, Inc., a life sciences company, engages in developing and commercializing products for researchers to unlock biological information. The company develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that provides workflow to make proteomic profiling, and the analysis of the samples needed to characterize the nature of the proteome. It intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as...
Financial Performance
In 2020, Seer, Inc's revenue was $656,000, an increase of 465.52% compared to the previous year's $116,000. Losses were -$32.78 million, 104.4% more than in 2019.
Financial StatementsAnalyst Forecast
According to 4 analysts, the average rating for Seer, Inc stock is "Buy." The 12-month stock price forecast is 55.00, which is an increase of 64.28% from the latest price.
News
Seer to Report Third Quarter Financial Results on November 9, 2021
REDWOOD CITY, Calif., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will report financ...
Seer to Present at the Morgan Stanley Global Healthcare Conference
REDWOOD CITY, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will be particip...
Seer Reports Second Quarter 2021 Financial Results
Expanded installed base and booked initial revenue for Proteograph Product Suite Expanded installed base and booked initial revenue for Proteograph Product Suite
Seer Bio Partners with Enlight Medical to Commercialize the Proteograph™ Product Suite in China
REDWOOD CITY, Calif. and BEIJING, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it has sig...
Earnings Previews: Airbnb, ContextLogic, Disney, Seer, SoFi
Of a dozen firms that reported earnings before markets opened on Wednesday, eight beat estimates and four missed.
Seer to Report Second Quarter Financial Results on August 12, 2021
REDWOOD CITY, Calif., July 13, 2021 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will report financ...
Biodesix Announces Presentation on Novel Proteomic Techniques in Partnership with Seer
BOULDER, Colo.--(BUSINESS WIRE)---- $BDSX #patientsfirst--Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company, today announced in partnership with Seer, Inc. (NASDAQ: SEER)...
Seer Reports First Quarter 2021 Financial Results
Second Phase of Commercialization Advances with the Addition of Multiple Limited Release Customers
Seer to Present at the BofA Securities 2021 Healthcare Conference
REDWOOD CITY, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will be participat...
Seer to Report First Quarter Financial Results on May 10, 2021
REDWOOD CITY, Calif., April 12, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will report fina...
Seer and SCIEX Sign Commercial Agreement to Offer End-to-End Unbiased Proteomics Solutions
Seer Proteograph™ Product Suite combined with SCIEX mass spectrometry technology to provide unbiased, deep proteomics workflows for labs of all types Seer Proteograph™ Product Suite combined with SCIEX ...
Seer Reports Fourth Quarter and Full Year 2020 Financial Results and Fuels Commercial Progress in 2021 with New Colla...
Added Salk Institute as collaboration customer and SCIEX as new commercial partner Added Salk Institute as collaboration customer and SCIEX as new commercial partner
Seer to Report Fourth Quarter and Full Year 2020 Financial Results on March 29, 2021
REDWOOD CITY, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will report fina...
Top 4th-Quarter Buys of Lee Ainslie's Maverick Capital
Lee Ainslie (Trades, Portfolio), the founder and CEO of Maverick Capital, recently disclosed the firm's portfolio changes for the fourth quarter of 2020, which ended on Dec. 31.
Seer to Present at the Cowen 41st Annual Healthcare Conference
REDWOOD CITY, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will be participa...
Seer Announces Closing of Public Offering of Common Stock
REDWOOD CITY, Calif. , Feb. 01, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., a life sciences company commercializing a disruptive new platform for proteomics, today announced the closing of an underwritten publ...
Seer Announces Pricing of Upsized Public Offering of Common Stock
REDWOOD CITY, Calif., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., a life sciences company commercializing a disruptive new platform for proteomics, today announced the pricing of an underwritten publi...
Seer Announces Proposed Public Offering of Common Stock
REDWOOD CITY, Calif., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Seer, Inc., a life sciences company commercializing a disruptive new platform for proteomics, today announced the commencement of a proposed under...
Seer Signs Commercial Agreement to Provide Complete End-to-End Solution for Unbiased, Deep, Rapid and Large-Scale Pro...
Combination of Thermo Fisher's market leading Orbitrap mass spectrometer portfolio with Seer Proteograph™ Product Suite to expand availability of end-to-end proteomics in new markets Combination of Ther...
Seer to Present at the 39th Annual J.P. Morgan Healthcare Conference
REDWOOD CITY, Calif., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a life sciences company focused on enabling exceptional scientific outcomes through the power of unbiased, deep, rapid ...
Notable Insider Buys Of the Past Week: Avis Budget, Biotech IPOs And More
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can ...
Seer Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Sh...
REDWOOD CITY, Calif., Dec. 08, 2020 (GLOBE NEWSWIRE) -- Seer, Inc., a life sciences company focused on enabling exceptional scientific outcomes through the power of unbiased, deep, rapid and scalable pr...
Biotech IPOs Stay Hot With Seer, Silverback Set To Trade
The hot category of initial public offerings in the biotechnology sector continues, with two set to trade Friday: Seer and Silverback Therapeutics. Both priced above their estimated range.
Seer Announces Pricing of Initial Public Offering
REDWOOD CITY, Calif., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Seer, Inc., a life sciences company focused on enabling exceptional scientific outcomes through the power of unbiased, deep, rapid and scalable pr...